Press Releases

Antiviral Drugs Market to Reach US$ 60.0 Bn by 2030

The worldwide Antiviral Drugs market measurement is anticipated to achieve USD 60.0 billion by 2030 and is anticipated to increase at a CAGR of -0.5% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38600

Growth Factors

 This is owing to the loss of patent protection of drugs and the high R&D investment required for developing antiviral drugs. However, the rising prevalence of viral infections and the presence of a potential pipeline for the treatment of HIV infection are expected to fuel the growth over the forecast period.

The increasing prevalence of influenza with other complications such as viral pneumonia, obesity, and the rising geriatric population drives the market growth. Moreover, pneumonia is one of the major causes of death in children worldwide. According to the WHO, Pneumonia causes 808,694 children’s deaths in 2017, accounting for 15.0% of all deaths of children under 5 years old. It is most prevalent in South Asia and the sub-Saharan African region.

Report Coverage

Report Scope Details
Market Size USD 60.0 billion by 2030
Growth Rate CAGR of -0.5% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Drug class, Type, Application
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Gilead Sciences, Inc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Cipla Inc.; Aurobindo Pharma; Dr. Reddy’s Laboratories Ltd.

Report Highlights

The reverse transcriptase inhibitors segment dominated the market for antiviral drugs and accounted for the largest revenue share of 51.0% in 2020. The segment is anticipated to maintain its dominance over the forecast period.

The high share of reverse transcriptase inhibitors can be attributed to the increasing diagnosis and treatment rate of HIV, as these medicines are mainly used to treat HIV infection and the high effectiveness of these drugs against viral infections. The protease inhibitors segment held the second-largest revenue share in 2020 and is anticipated to witness a CAGR of -1.5% over the forecast period.

The branded segment dominated the market and accounted for the largest revenue share of 59.2% in 2020. The segment is expected to maintain its dominance over the forecast period. Branded antiviral medicines such as Biktarvy, Genvoya, Triumeq, Mavyret, and Prezista hold a significant share of the market. Increasing demand for the generic version of antiviral drugs in developing countries due to its cost-effectiveness is driving the generics segment.

The HIV segment dominated the market and held the largest revenue share of 46.1% in 2020. The segment is expected to witness the fastest growth rate over the forecast period. The high prevalence of HIV infection coupled with a high treatment rate, presence of branded drugs, and government initiatives to increase the treatment rate is estimated to drive the market at a higher growth rate.

North America dominated the market and accounted for the largest revenue share in 2020. The region is expected to witness a CAGR of -1.9% over the forecast period. The market decline can be attributed to the loss of market exclusivity of branded drugs, increasing vaccination rate against viral infections, and government initiatives to reduce the incidence of viral infections.

Key Players

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.

Market Segmentation

  • Drug Class
    • DNA Polymerase Inhibitors
    • Reverse Transcriptase Inhibitors
    • Protease Inhibitors
    • Neuraminidase Inhibitors
    • Others
  • Type
    • Branded
    • Generics
  • Application
    • HIV
    • Hepatitis
    • Herpes
    • Influenza
    • Others
  • Regional
    • North America
      • U.S
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia
      • South Korea
    • Latin America
      • Argentina
      • Brazil
      • Mexico
      • Colombia
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38600

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Antiviral Drugs Market, By Drug Class

7.1.  Antiviral Drugs Market, by Drug Class, 2021-2030

7.1.1.    DNA Polymerase Inhibitors

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Reverse Transcriptase Inhibitors

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Protease Inhibitors

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Neuraminidase Inhibitors

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Antiviral Drugs Market, By Type

8.1.  Antiviral Drugs Market, by Type, 2021-2030

8.1.1.    Branded

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Generics

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Antiviral Drugs Market, By Application

9.1.  Antiviral Drugs Market, by Application, 2021-2030

9.1.1.    HIV

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Hepatitis

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Herpes

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Influenza

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Antiviral Drugs Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.2.  Market Revenue and Forecast, by Type (2017-2030)

10.1.3.  Market Revenue and Forecast, by Application (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Application (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Application (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.2.  Market Revenue and Forecast, by Type (2017-2030)

10.2.3.  Market Revenue and Forecast, by Application (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Application (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Application (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Application (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Application (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.2.  Market Revenue and Forecast, by Type (2017-2030)

10.3.3.  Market Revenue and Forecast, by Application (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Application (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Application (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Application (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Application (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.2.  Market Revenue and Forecast, by Type (2017-2030)

10.4.3.  Market Revenue and Forecast, by Application (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Application (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Application (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Application (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Application (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.2.  Market Revenue and Forecast, by Type (2017-2030)

10.5.3.  Market Revenue and Forecast, by Application (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Application (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Application (2017-2030)

Chapter 11.  Company Profiles

11.1.              F. Hoffmann-La Roche Ltd.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              GlaxoSmithKline plc

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              AbbVie

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Merck & Co., Inc.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Johnson & Johnson Services, Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Bristol-Myers Squibb Company

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Cipla Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Aurobindo Pharma

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Dr. Reddy’s Laboratories Ltd.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38600

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Show More

Related Articles

Back to top button